Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy

33Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The analgesic efficacy and safety of 2 phase 2b studies of EMA401 (a highly selective angiotensin II type 2 receptor antagonist) in patients with postherpetic neuralgia (EMPHENE) and painful diabetic neuropathy (EMPADINE) were reported. These were multicentre, randomised, double-blind treatment studies conducted in participants with postherpetic neuralgia or type I/II diabetes mellitus with painful distal symmetrical sensorimotor neuropathy. Participants were randomised 1:1:1 to either placebo, EMA401 25 mg, or 100 mg twice daily (b.i.d) in the EMPHENE and 1:1 to placebo or EMA401 100 mg b.i.d. in the EMPADINE. The primary outcome for both the studies was change in weekly mean of the 24-hour average pain score, using a numeric rating scale from baseline to week 12. Both the studies were prematurely terminated due to preclinical hepatotoxicity on long-term dosing, although not observed in these studies. Out of the planned participants, a total of 129/360 (EMPHENE) and 137/400 (EMPADINE) participants were enrolled. The least square mean reduction in numeric rating scale pain score was numerically in favour of EMA401 100 mg arm in both EMPHENE (treatment difference: -0.5 [95% confidence interval: -1.6 to 0.6; P value: 0.35]) and EMPADINE (treatment difference: -0.6 [95% confidence interval: -1.4 to 0.1; P value: 0.10]) at the end of week 12. However, as the studies were terminated prematurely, no firm conclusion could be drawn but the consistent clinical improvement in pain intensity reduction across these 2 studies in 2 different populations is worth noting.

References Powered by Scopus

Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis

2955Citations
N/AReaders
Get full text

Neuropathic pain in the general population: A systematic review of epidemiological studies

1205Citations
N/AReaders
Get full text

A new definition of neuropathic pain

1120Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery

49Citations
N/AReaders
Get full text

The Angiotensin AT<inf>2</inf> Receptor: Froma Binding Site to a Novel Therapeutic Target

48Citations
N/AReaders
Get full text

Advances in the treatment of neuropathic pain

47Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rice, A. S. C., Dworkin, R. H., Finnerup, N. B., Attal, N., Anand, P., Freeman, R., … Pandhi, S. (2021). Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain, 162(10), 2578–2589. https://doi.org/10.1097/j.pain.0000000000002252

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

59%

Researcher 5

29%

Professor / Associate Prof. 1

6%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

39%

Chemistry 5

28%

Pharmacology, Toxicology and Pharmaceut... 4

22%

Neuroscience 2

11%

Save time finding and organizing research with Mendeley

Sign up for free